JNJ - Johnson & Johnson
| Previous close | 130.41 |
| Open | 129.63 |
| Bid | 129.92 x 900 |
| Ask | 130.36 x 800 |
| Day's range | 129.36 - 131.19 |
| 52-week range | 121.00 - 148.99 |
| Volume | 4,534,748 |
| Avg. volume | 7,291,306 |
| Market cap | 342.591B |
| Beta (3Y monthly) | 0.73 |
| PE ratio (TTM) | 21.61 |
| EPS (TTM) | 6.02 |
| Earnings date | 15 Oct 2019 |
| Forward dividend & yield | 3.80 (2.92%) |
| Ex-dividend date | 2019-08-26 |
| 1y target est | 149.35 |
- Zacks
Top Stock Reports for Johnson & Johnson, Boeing & Broadcom
Top Stock Reports for Johnson & Johnson, Boeing & Broadcom
- Zacks
J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use
J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.
- Zacks
FDA Warns About Safety of Breast Implant: 3 Stocks at Risk
As breast implant-related health hazards surface, a few manufacturing companies might bear a brunt.
- Zacks
Are You Looking for a High-Growth Dividend Stock? Johnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
- Zacks
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
Johnson & Johnson (JNJ) closed the most recent trading day at $129.64, moving +0.08% from the previous trading session.
- Zacks
Should You Buy Vegan Stocks & ETF?
Beyond Meat is one of the hottest IPOs this year and a new ETF aims to capitalize on the trend.
- Zacks
Novartis Announces New Data on Spondylitis Drug Cosentyx
Novartis (NVS) announces new positive data from a phase III study on Cosentyx in patients with active nr-axSpA.
- Zacks
Karyopharm Signs $150M Royalty Agreement to Support Xpovio
Karyopharm (KPTI) signs royalty agreement with HealthCare Royalty Partners for up to $150 million to fund Xpovio's commercialization and development.
- Zacks
J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis
J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.
- Zacks
AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure
The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.
- Zacks
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study
Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.
- Financial Times
CMR Surgical hits £1bn valuation as it rolls out robots for surgery
CMR Surgical, a five-year-old medical robotics company based in Cambridge, has raised £195m in a funding round that pushed the value of the company to more than £1bn ahead of the launch of its first product. The Series C financing — the largest in Europe‘s medical technology sector, according to CMR — will “fully fund the global commercialisation of the business”, said Martin Frost, chief executive. Versius is designed to provide surgeons with multiple robotic arms to carry out a range of keyhole or minimal access procedures.
- Yahoo Finance
Startup uses remittances to remove 'time and distance' from health care
Hoy Health launched less than two years ago, but sees strong growth potential in paving the way to the Latin American health care market.
- Zacks
Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others
Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
- Zacks
J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients
J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.
- Zacks
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
Johnson & Johnson (JNJ) closed the most recent trading day at $131.17, moving +1.25% from the previous trading session.
- Zacks
Mallinckrodt to Divest Contract Manufacturing Unit, Stock Up
Mallinckrodt's (MNK) shares gain as it agrees to sell its contract manufacturing unit to raise cash to settle liabilities from various opioid litigations.
- Zacks
Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally
Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.
- Zacks
Theravance Announces Positive Early Data on JAK Inhibitor
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.
- Zacks
Mallinckrodt (MNK) to Resolve Opioid Cases with Ohio Counties
Mallinckrodt (MNK) reaches a settlement in principle with a couple of Ohio counties for opioid litigation.
- Zacks
The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers
The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers
- Simply Wall St.
An Intrinsic Calculation For Johnson & Johnson (NYSE:JNJ) Suggests It's 43% Undervalued
How far off is Johnson & Johnson (NYSE:JNJ) from its intrinsic value? Using the most recent financial data, we'll take...
- Motley Fool
Here's Why Arrowhead Pharmaceuticals Rose 17.6% in August
The biopharma announced fiscal third-quarter 2019 operating results and multiple updates from the pipeline.
- Motley Fool
The 11 Biggest Dividend Stocks on the Market
Some of the biggest companies on earth are giving their investors a share of the profits each quarter through dividends.
- Zacks
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs
Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
